Metabolic Syndrome Clinical Trial
— NAFLDOfficial title:
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Verified date | December 2022 |
Source | Hippocration General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet medical needs. Aim of this study is to investigate the blood levels of three hormonal systems related to obesity, insulin resistance and inflammation in patients with different stages of NAFLD, in order to identify potential diagnostic markers. Study aim: To compare the blood levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like (FSTL)3, activin B), c) IGF axis (insulin-like growth factor (IGF)-1, total and intact IGF binding protein (IGFBP)-3 and IGFBP-4, in 18 individuals with early stage NAFLD vs. 14 controls To explore the levels of GDF-15, total and intact, in NAFLD versus obese controls (OC) at baseline and during oral glucose tolerance tests (OGTTs)
Status | Completed |
Enrollment | 32 |
Est. completion date | May 30, 2017 |
Est. primary completion date | May 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Individuals with liver ultrasound imaging - Adults Exclusion Criteria: - The presence of any secondary cause of fatty liver, such as viral, alcoholic, autoimmune and drug-induced hepatitis. |
Country | Name | City | State |
---|---|---|---|
Greece | Hippokration General Hospital | Thessaloniki |
Lead Sponsor | Collaborator |
---|---|
Hippocration General Hospital |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proglucagon-derived hormones | glucagon-like peptide GLP-1 (pg/ml) | baseline | |
Primary | Proglucagon-derived hormones | glucagon-like peptide GLP-2 (pg/ml) | baseline | |
Primary | Proglucagon-derived hormones | glicentin (pmol/l) | baseline | |
Primary | Proglucagon-derived hormones | oxyntomodulin (pg/ml) | baseline | |
Primary | Proglucagon-derived hormones | glucagon (pg/ml) | baseline | |
Primary | Proglucagon-derived hormones | major proglucagon fragment [MPGF]) (ng/ml) | baseline | |
Primary | Follistatins-activins | follistatin-like (FSTL)3 (ng/ml) | baseline | |
Primary | Follistatins-activins | activin B (pg/ml) | baseline | |
Primary | IGF axis | insulin-like growth factor (IGF)-1 (ng/ml) | baseline | |
Primary | IGF axis | total and intact IGF binding protein (IGFBP)-3 and IGFBP-4 (ng/ml) | baseline | |
Primary | Liver ultrasound | Estimation of echogenicity, hepatomegaly, and intra-hepatic vascular blurring (1: Intermediate, 1-2: Intermediate to Moderate, 2: Moderate, 3: Severe) | baseline | |
Primary | GDF-15 | Total and intact Growth differentiation factor 15 (pg/mL) | baseline | |
Secondary | Body Mass Index (BMI) | BMI is calculated as weight in kilograms divided by height in meters squared. | baseline | |
Secondary | Biochemical parameters | Glucose (mg/dl) | baseline | |
Secondary | Biochemical parameters | serum aspartate transaminase (AST) (U/L), ALT (U/L) | baseline | |
Secondary | Biochemical parameters | gamma-glutamyltransferase (GGT) (U/L) | baseline | |
Secondary | Biochemical parameters | total cholesterol (mg/dl), triglycerides (mg/dl) and high density lipoprotein-cholesterol (HDL-C) (mg/dl), low density lipoprotein-cholesterol (LDL-C) (mg/dl) | baseline | |
Secondary | Biochemical parameters | insulin (µU/ml) | baseline | |
Secondary | Metabolomics and lipidomics analysis | Measured with nuclear magnetic resonance spectroscopy (NMR) by Labcorp (Morrisville, USA). | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |